Cargo Therapeutics, Inc. CRGX
We take great care to ensure that the data presented and summarized in this overview for CARGO Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in CRGX
Top Purchases
Top Sells
About CRGX
Insider Transactions at CRGX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 19
2025
|
Anup Radhakrishnan |
SELL
Sale (or disposition) back to the issuer
|
Direct |
63,436
-100.0%
|
$253,744
$4.38 P/Share
|
|
Aug 18
2025
|
Anup Radhakrishnan |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
57,345
-47.48%
|
$229,380
$4.38 P/Share
|
|
Jul 02
2025
|
Anup Radhakrishnan |
SELL
Open market or private sale
|
Direct |
1,632
-1.33%
|
$6,528
$4.18 P/Share
|
|
May 14
2025
|
Anup Radhakrishnan |
SELL
Open market or private sale
|
Direct |
27,404
-18.29%
|
$82,212
$3.84 P/Share
|
|
May 12
2025
|
Anup Radhakrishnan |
BUY
Grant, award, or other acquisition
|
Direct |
72,500
+32.61%
|
-
|
|
Apr 03
2025
|
Anup Radhakrishnan |
SELL
Open market or private sale
|
Direct |
1,629
-2.06%
|
$6,516
$4.0 P/Share
|
|
Mar 14
2025
|
Shishir Gadam Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+40.14%
|
-
|
|
Mar 14
2025
|
Gina Chapman President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+39.69%
|
-
|
|
Mar 14
2025
|
Ginna Laport Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+50.0%
|
-
|
|
Mar 14
2025
|
Anup Radhakrishnan |
BUY
Grant, award, or other acquisition
|
Direct |
72,500
+47.87%
|
-
|
|
Sep 19
2024
|
Gina Chapman President & CEO |
SELL
Open market or private sale
|
Direct |
2,975
-2.78%
|
$74,375
$25.03 P/Share
|
|
Sep 19
2024
|
Gina Chapman President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,975
+2.71%
|
$14,875
$5.03 P/Share
|
|
Sep 18
2024
|
Gina Chapman President & CEO |
SELL
Open market or private sale
|
Direct |
7,166
-6.45%
|
$179,150
$25.09 P/Share
|
|
Sep 18
2024
|
Gina Chapman President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,166
+6.06%
|
$35,830
$5.03 P/Share
|
|
Sep 18
2024
|
Anup Radhakrishnan |
SELL
Open market or private sale
|
Direct |
1,600
-19.89%
|
$40,000
$25.28 P/Share
|
|
Sep 18
2024
|
Anup Radhakrishnan |
BUY
Exercise of conversion of derivative security
|
Direct |
1,600
+16.59%
|
$8,000
$5.03 P/Share
|
|
May 30
2024
|
Samsara Bio Capital Gp, LLC |
BUY
Open market or private purchase
|
Indirect |
294,000
+6.24%
|
$4,998,000
$17.0 P/Share
|
|
Jan 12
2024
|
Rtw Investments, LP > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
1,842,499
-26.25%
|
-
|
|
Nov 14
2023
|
Samsara Bio Capital Gp, LLC |
BUY
Open market or private purchase
|
Indirect |
666,666
+13.92%
|
$9,999,990
$15.0 P/Share
|
|
Nov 14
2023
|
Samsara Bio Capital Gp, LLC |
BUY
Conversion of derivative security
|
Indirect |
3,381,323
+49.46%
|
-
|
Last 12 Months Summary
Buy / Acquisition
455K
Shares
From
4
Insiders
| Grant, award, or other acquisition | 455K shares |
|---|
Sell / Disposition
151K
Shares
From
3
Insiders
| Sale (or disposition) back to the issuer | 63.4K shares |
|---|---|
| Open market or private sale | 30.7K shares |
| Disposition due to a tender of shares in a change of control transaction | 57.3K shares |